Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 31

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 31
---
 could become less profitable from product sales and our products could become
obsolete.

There are many reasons why a competitor might be more successful than
us, including:

| ● | Financial Resources. Some competitors have greater                                        
 financial resources and can afford more technical and developmental setbacks than we can. |

| ● | Greater Experience.                                                                                                                  
 Some competitors have been in the biotechnology business longer than we have. They have greater experience than us in critical areas 
 like clinical testing, obtaining regulatory approval and sales and marketing. This experience or their name recognition may give     
 them a competitive advantage over us. In certain international markets, local companies may be given preferential treatment by local 
 physicians and hospitals.                                                                                                            |

| ● | Superior Patent Position.                                                                                                          
 Competitors may have more robust patent portfolios or exclusive rights that block or limit our ability to develop or commercialize 
 similar technologies. If we are unable to enforce our patents or secure necessary licenses to third-party intellectual property,   
 our competitive position may be weakened.                                                                                          |

| ● | Faster to Market.                                                                                                                 
 Some companies with competitive technologies may move through stages of development, approval, and marketing faster than us. If a 
 competitor receives FDA approval before us, then it will be authorized to sell its products before we can sell ours. Because the  
 first company “to market” often has a significant advantage over others, a second place position could result in less             
 than anticipated sales.                                                                                                           |

| ● | Reimbursement Allowed.                                                                                                                
 In the U.S., third party payers, such as Medicare, may reimburse physicians and hospitals for competitors’ products but not           
 for our own human-use products or reimburse our competitors since they offer less cost or have stronger negotiation position (like    
 large competitors offer for favorable pricing since they sell in larger quantities. This would significantly affect our ability to    
 sell our human-use products in the U.S. and would have a negative impact on revenue and our business as a whole. Outside of the U.S., 
 reimbursement and funding policies vary widely.                                                                                       |

Risks Related to Protection of Intellectual Property

Our inability to protect our trademarks, patents and trade secrets may prevent us from successfully marketing our products and competing effectively.

Failure to protect our
intellectual property could harm our brand and our reputation and adversely affect our ability to compete effectively. Further, enforcing
or defending our intellectual property rights, including our licensing rights trademarks, patents, copyrights and trade secrets, could
result in the expenditure of significant financial and managerial resources. We regard